$QSI

Vieceli John S. sold $28K of QSI

Vieceli John S. (Chief Product Officer) sold 30,223 shares of Quantum-Si Inc (QSI) at an average of $0.93 ($0.90–$0.96) across 2 trades over 2026-06-22 to 2026-06-23.

Original reporting
SEC EDGAR · Vieceli John S.
Published Jun 25, 2026, 12:17 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 12:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$QSI
Neutral
medium confidence
Mentioned
$QSI
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QSINeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by the Chief Product Officer (30,223 shares) with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may monitor for sentiment impact, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article provides trade prices and post-sale holdings but no context on compensation, tax obligations, or whether sales were part of broader personal liquidity needs.

Relevance 3/10Novelty 5/10Timing: as-of the latest SEC Form 4 filing (filed 2026-06-24)

Background

The article is an SEC Form 4 insider transaction disclosure for Quantum-Si Inc (QSI).

Company-level read

Ticker impact

$QSINeutralMedium confidence
Context

SEC Form 4 shows QSI CPO Vieceli John S. sold 30,223 shares in open-market trades at ~$0.899–$0.9574 (avg $0.9282).

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include new operational guidance, contracts, litigation, or financing details—so the tradable signal is weak.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/taxes; absence of a 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • Quantum-Si Inc

    Subject of the Form 4 insider transaction disclosure.

  • Vieceli John S.

    Chief Product Officer who sold shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QSIMed

Quantum-Si Q2 Earnings Call Highlights

Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.

$QSIMedAI 8/10

Quantum-Si (QSI) Stock Falls on Q2 2026 Earnings

Quantum-Si Inc. (QSI) reported Q2 2026 revenue of $344,000, above an analyst estimate of $305,020. Diluted EPS was -$0.11, slightly better than expected. The company posted gross profit of $172,000 and an operating loss of $25.6 million, with net loss of $23.5 million. Cash was $23.7 million. Shares fell 1.19% after the release.

$QSIMed

Quantum-Si Inc (QSI): Results of Operations and Financial Condition

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new mark